London, UK, 16 March 2023

Edison issues review on The Biotech Growth Trust (BIOG)

The Biotech Growth Trust (BIOG) has been managed by global healthcare specialist OrbiMed Capital since May 2005. During its tenure, the trust has outperformed its benchmark, the NASDAQ Biotechnology Index. OrbiMed favours the prospects for emerging (smaller-cap) biotech stocks rather than large-cap biotech businesses, as this is where the most industry innovation occurs. BIOG's manager, Geoff Hsu, considers innovation to be the most important driver of the biotech sector's long-term positive performance. He believes that we remain in a 'golden era', evidenced by an expanding pipeline of new drug candidates across all therapeutic areas. The manager expects an acceleration in mergers and acquisitions (M&A) as major pharma companies, facing patent expirations, seek to bolster their product pipelines by acquiring smaller biotech companies.

BIOG's 9.2% share price discount to cum-income NAV is wider than the 3.9% to 6.8% range of average discounts over the last one, three, five and 10 years. There is potential for a narrower discount; the trust considerably outperformed its benchmark between Q120 and Q121, and during this time BIOG's discount narrowed, and its shares regularly traded close to NAV. 

Click here to view the full report or here to sign up to receive research as it is published.

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Mel Jenner +44 (0)20 3077 5700 investmenttrusts@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn        www.linkedin.com/company/edison-group-/

Twitter             www.twitter.com/Edison_Inv_Res

YouTube       www.youtube.com/edisonitv